Clinical Report: CGM Shows Potential for Diagnosing Diabetes in Pregnancy
Overview
Revise to emphasize CGM's current status and the necessity for further validation.
Background
Gestational diabetes mellitus (GDM) poses significant risks for both maternal and neonatal health, making accurate diagnosis essential. The traditional diagnostic method, the oral glucose tolerance test (OGTT), has limitations, prompting interest in alternative methods such as continuous glucose monitoring (CGM). Understanding the potential of CGM in diagnosing GDM could enhance screening strategies and improve pregnancy outcomes.
Data Highlights
No numerical data available.
Key Findings
CGM metrics can differentiate patients who later develop GDM from those who do not.
Higher mean glucose levels and greater glucose variability were observed as early as 13-14 weeks of gestation in patients diagnosed with GDM.
Some CGM-derived measures demonstrated moderate predictive performance with area under the receiver operating curve values approaching 0.8.
Increased time above target glucose levels correlated with adverse neonatal outcomes, including large-for-gestational-age infants and neonatal hypoglycemia.
CGM-detected glucose excursions showed stronger correlations with birth weight centiles compared to standard OGTT testing.
Current evidence is insufficient to support CGM as a standalone diagnostic test for GDM.
Clinical Implications
Healthcare providers should be aware that while CGM may provide valuable insights into glucose patterns during pregnancy, it cannot currently replace the OGTT for diagnosing GDM. Further research is needed to establish standardized diagnostic thresholds for CGM to enhance its clinical utility.
Conclusion
Strengthen the conclusion by reiterating the need for rigorous validation studies.
A large BRFSS analysis points to persistent screening disparities among sexual orientation and gender identity minority respondents, with particularly large gaps in some gender identity minority groups.
Single-nucleus sequencing of menstrual fluid identified epithelial gene signatures and prioritized five candidate biomarkers that warrant validation in larger studies.
